ELTX
Income statement / Annual
Last year (2023), Elicio Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Elicio Therapeutics, Inc.'s net income was -$35.20 M.
See Elicio Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$0.00 |
$0.00 |
$28.31 M |
$2.88 M |
$1.49 M |
$4.03 M |
$6.58 M |
$7.30 M |
| Cost of Revenue |
$1.17 M
|
$1.06 M
|
$1.23 M
|
$1.82 M
|
$1.14 M
|
$380,000.00
|
$3.17 M
|
$3.67 M
|
| Gross Profit |
-$1.17 M
|
-$1.06 M
|
$27.08 M
|
$1.06 M
|
$351,000.00
|
$3.65 M
|
$3.41 M
|
$3.62 M
|
| Gross Profit Ratio |
0
|
0
|
0.96
|
0.37
|
0.24
|
0.91
|
0.52
|
0.5
|
| Research and Development Expenses |
$22.68 M
|
$18.10 M
|
$17.93 M
|
$12.72 M
|
$9.54 M
|
$9.15 M
|
$196,008.00
|
$0.00
|
| General & Administrative Expenses |
$11.90 M
|
$5.63 M
|
$7.54 M
|
$3.00 M
|
$2.80 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.90 M
|
$5.63 M
|
$7.54 M
|
$3.00 M
|
$2.80 M
|
$8.84 M
|
$3.61 M
|
$4.04 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$34.58 M
|
$23.73 M
|
$25.47 M
|
$15.72 M
|
$12.34 M
|
$17.99 M
|
$3.81 M
|
$4.04 M
|
| Cost And Expenses |
$35.75 M
|
$23.73 M
|
$25.47 M
|
$15.72 M
|
$12.34 M
|
$18.37 M
|
$6.98 M
|
$7.72 M
|
| Interest Income |
$373,000.00
|
$64,829.00
|
$3,392.00
|
$8,942.00
|
$81,481.00
|
$252,000.00
|
$0.00
|
$0.00
|
| Interest Expense |
$1.06 M
|
$3.60 M
|
$876,442.00
|
$0.00
|
$0.00
|
$0.00
|
$300,432.00
|
$307,450.00
|
| Depreciation & Amortization |
$1.17 M
|
$1.06 M
|
$801,000.00
|
$628,000.00
|
$496,000.00
|
$2,000.00
|
$460,344.00
|
$463,216.00
|
| EBITDA |
-$32.97 M |
-$23.55 M |
-$51.93 M |
-$15.53 M |
-$40.16 M |
-$14.34 M |
$62,540.00 |
$1.96 M |
| EBITDA Ratio |
0
|
0
|
-0.89
|
-5.39
|
-8.23
|
-3.56
|
0.01
|
0.01
|
| Operating Income Ratio |
0
|
0
|
-0.9
|
-5.46
|
-8.3
|
-3.56
|
-0.06
|
-0.06
|
| Total Other Income/Expenses Net |
$550,000.00
|
-$4.47 M
|
-$926,011.00
|
$8,942.00
|
-$28.32 M
|
-$5.68 M
|
$2.13 M
|
$1.61 M
|
| Income Before Tax |
-$35.20 M
|
-$28.21 M
|
-$26.40 M
|
-$15.71 M
|
-$12.26 M
|
-$20.03 M
|
$1.73 M
|
$1.19 M
|
| Income Before Tax Ratio |
0
|
0
|
-0.93
|
-5.46
|
-8.25
|
-4.97
|
0.26
|
0.16
|
| Income Tax Expense |
$0.00
|
$3.60 M
|
$876,442.00
|
$8,942.00
|
$81,481.00
|
$0.00
|
$452,778.00
|
$201,858.00
|
| Net Income |
-$35.20 M
|
-$28.21 M
|
-$26.40 M
|
-$15.71 M
|
-$12.26 M
|
-$20.03 M
|
$632,241.00
|
$307,303.00
|
| Net Income Ratio |
0
|
0
|
-0.93
|
-5.46
|
-8.25
|
-4.97
|
0.1
|
0.04
|
| EPS |
-6.96 |
-9.1 |
-8.25 |
-1.93 |
-1.5 |
-6.79 |
103.31 |
50.21 |
| EPS Diluted |
-6.96 |
-9.1 |
-8.25 |
-1.93 |
-1.5 |
-6.79 |
103.31 |
50.21 |
| Weighted Average Shares Out |
$5.06 M
|
$3.10 M
|
$3.20 M
|
$8.15 M
|
$8.15 M
|
$2.95 M
|
$6,120.00
|
$6,120.00
|
| Weighted Average Shares Out Diluted |
$5.06 M
|
$3.10 M
|
$3.20 M
|
$8.15 M
|
$8.15 M
|
$2.95 M
|
$6,120.00
|
$6,120.00
|
| Link |
|
|
|
|
|
|
|
|
